<DOC>
	<DOCNO>NCT02848443</DOCNO>
	<brief_summary>The main purpose study assess safety tolerability determine recommend phase 2 dose S 95005 give combination oxaliplatin patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Study S 95005 Combination With Oxaliplatin Metastatic Colorectal Cancer</brief_title>
	<detailed_description>This one-arm study , conduct 2 part : - A dose-escalation part determine Maximum Tolerated Dose ( MTD ) S 95005 combination oxaliplatin . - An expansion part patient treat recommend dose define dose escalation part study evaluate safety , PK , preliminary efficacy S 95005 combination oxaliplatin either bevacizumab nivolumab .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>Age 18 year old . Histologically confirm metastatic colorectal cancer pretreated least one line standard chemotherapy . Restaging scan within 28 day first study drug intake . During doseescalation part , patient must least one evaluable measurable metastatic lesion ; expansion part , patient must least one measurable metastatic lesion . Life expectancy 3 month . Performance status Eastern Cooperative Oncology Group ( ECOG ) : 01 . Adequate bone marrow , liver , kidney function . For patient receive bevacizumab : coagulation parameter normal limit therapeutic limit patient treat anticoagulant . For patient receive nivolumab : patient eligible tumour biopsy agree two sequential biopsy study . Women childbearing potential must negative pregnancy test . Female participant childbearing potential male participant partner childbearing potential must agree use highly effective birth control method . Women female partner use hormonal contraceptive must also use barrier method . Capacity take oral tablet ( ) without difficulty . Has provide write informed consent . Is willing able comply schedule visit study procedure . Grade 2 high peripheral neuropathy . During expansion part , patient recurrence within 6 month completion adjuvant chemotherapy oxaliplatin . Patients brain metastasis leptomeningeal metastasis . Other malignancy within last 3 year ( except basal cell carcinoma noninvasive/in situ cervical cancer ) Has certain recent treatment e.g . major surgery , field radiation , participation another interventional study , within specified time frame prior study drug administration . Certain serious illness serious medical condition For patient receive bevacizumab : history allergic reactions/hypersensitivity bevacizumab , component use formulation , Chinese Hamster Ovary ( CHO ) cell product recombinant human humanise antibody . Grade 3 high hypersensitivity reaction oxaliplatin garde 12 hypersensitivity reaction oxaliplatin control premedication . Patient previously treat S 95005 history allergic reaction attribute compound similar composition S 95005 excipient . Patient hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption . Any condition , judgment Investigator , may affect patient 's ability understand sign inform consent fully comply study procedure . Pregnancy breast feeding . For patient plan receive nivolumab : Patients active autoimmune disease history clinically severe autoimmune disease . Patients condition require systemic treatment either corticosteroid ( &gt; 20 mg daily prednisone equivalent ) immunosuppressive medication within specified time frame prior first study drug intake . Prior treatment antiPD1 , antiPDL1 , antiprogrammed cell death ligand2 , antiCD137 , antiOX40 , antiCD40 , anticytotoxic T lymphocyteassociated antigen4 antibody ( CTLA4 ) , immune checkpoint inhibitor . Prior event immunemediated pneumonitis , immunemediated colitis , immunemediated hepatitis , immunemediated endocrinopathies , immunemediated nephritis renal dysfunction , immunemediated rash , immunemediated encephalitis . Allergic reactions/hypersensitivity nivolumab component use formulation previous severe hypersensitivity reaction treatment another monoclonal antibody . Has know history active tuberculosis ( Bacillus Tuberculosis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>metastatic</keyword>
	<keyword>colorectal</keyword>
	<keyword>cancer</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>dose-escalation</keyword>
	<keyword>Lonsurf</keyword>
	<keyword>nivolumab</keyword>
	<keyword>bevacizumab</keyword>
</DOC>